A Phase I Trial of TEW-7197 in Combination With Pomalidomide (POM) in Relapsed or Relapsed and Refractory Multiple Myeloma (RRMM)
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Pomalidomide (Primary) ; Vactosertib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 06 Nov 2019 Results (n=10; as of 30 July 2019) assessing safety and preliminary efficacy of combination of pomalidomide and vactosertib, released in 61st Annual Meeting and Exposition of the American Society of Hematology
- 25 Apr 2019 Planned End Date changed from 1 May 2019 to 1 Dec 2019.
- 25 Apr 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Dec 2019.